MorphoSys Announces Voluntary Delisting From the Nasdaq Global Market
MorphoSys Announces Voluntary Delisting From the Nasdaq Global Market
EQS-News: MorphoSys AG / Key word(s): Delisting Media Release Planegg/Munich, Germany, July 12, 2024 MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act"). MorphoSys currently anticipates that it will file with the Securities and Exchange Commission (the "SEC") a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) of the Exchange Act, relating to the delisting and deregistration on or about July 25, 2024, with the delisting of the ADSs taking effect no earlier than ten days thereafter. As a result, MorphoSys expects that the last trading day on Nasdaq will be on or about August 2, 2024. Following the delisting, any trading in MorphoSys' ADSs would occur only in privately negotiated sales and potentially on an over-the-counter market if a broker makes a market in the ADSs. There is no guarantee, however, that a broker will make such a market or that trading of the ADSs will continue on an over-the-counter market or otherwise. The Supervisory Board of MorphoSys authorized the delisting of the ADSs as required by the delisting agreement signed by MorphoSys, Novartis BidCo AG and Novartis AG (hereinafter collectively referred to as "Novartis"). On July 4, 2024, Novartis launched its public delisting purchase offer for all outstanding no-par value bearer shares of MorphoSys. In addition, Novartis has informed MorphoSys of its intention to merge MorphoSys into Novartis (the "Merger Squeeze-out"). The conclusion and notarization of the merger agreement between MorphoSys AG and Novartis BidCo Germany AG will take place shortly. The effectiveness of the merger squeeze-out is still subject to approval by the MorphoSys AG Annual General Meeting and the registration of both the transfer resolution and the merger in the commercial register at the seat of MorphoSys AG, as well as the registration of the merger in the commercial register at the seat of Novartis BidCo Germany AG. About MorphoSys Forward-Looking Statements The forward-looking statements contained in this communication represent the judgment of MorphoSys as of the date of this communication and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: MorphoSys' ability to file a Form 25 and the timing of such filing; the last trading day of the ADSs on the Nasdaq Global Market; MorphoSys' ability to file a Form 15 and the timing of such filing; the timing of effectiveness of the Form 15; the effects of the acquisition of MorphoSys by Novartis AG on relationships with employees, other business partners or governmental entities; that Novartis BidCo AG and Novartis AG may not realize the potential benefits of the acquisition of MorphoSys by Novartis AG; potential operational difficulties with integrating MorphoSys with Novartis AG; that MorphoSys' expectations may be incorrect; the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements; MorphoSys' reliance on collaborations with third parties; estimating the commercial potential of MorphoSys' development programs; and other risks indicated in the risk factors included in MorphoSys' filings with the SEC, including MorphoSys' Annual Report on Form 20-F. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this communication. MorphoSys' expressly disclaims any obligation to update any such forward-looking statements in this communication to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. For more information, please contact:
12.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
MorphoSys AG / 關鍵詞:退市
MorphoSys宣佈自納斯達克全球市場自願退市 媒體新聞稿 德國,普蘭格/慕尼黑,2024年7月12日 MorphoSys宣佈自納斯達克全球市場自願撤牌 MorphoSys監事會根據MorphoSys、諾華子公司BidCo AG和諾華製藥簽署的退市協議要求授權退市。2024年7月4日,諾華發起所有未償還無面額股票收購報價。 MorphoSys目前預計,將提交《1934年交易所法》第12(b)條下的上市和/或註冊撤銷通知表格25表,有關從納斯達克股票市場除牌和註銷手續,時間不早於2024年7月25日的日期,並於之後的十天內生效。因此,MorphoSys預計,納斯達克的最後交易日爲2024年8月2日左右。 另外,諾華已告知MorphoSys有意將MorphoSys併入諾華(擬定的併購)。 MorphoSys AG和諾華子公司BidCo Germany AG之間的合併協議的締結和公證將很快進行。合併強制註銷的有效性仍需獲得MorphoSys AG股東大會批准,以及在MorphoSys AG註冊地商業登記簿上註冊股份轉讓決議和合並事項,以及在諾華銀行子公司德國商業登記簿上註冊合併事項。 MorphoSys的使命驅動我們:爲癌症患者帶來更多的生活。作爲一家全球性生物製藥公司,我們開發和提供創新藥品,旨在重新定義癌症的治療。MorphoSys總部位於德國Planegg,其美國業務總部位於馬薩諸塞州的波士頓。欲了解更多信息,請訪問我們 ,並關注我們的Twitter X和LinkedIn。 此通信涉及某些關於MorphoSys、Novartis和退市要約的前瞻性陳述,這些前瞻性陳述涉及重大風險和不確定性。前瞻性陳述包括任何含有“預計”、“相信”、“估計”、“期望”、“意圖”、“目標”、“可能”、“計劃”、“預測”、“項目”、“尋求”、“目標”、“潛在”、“將”、“可能”、“應該”、“持續”或類似表述的陳述。在此通信中,MorphoSys的前瞻性陳述包括有關完成退市要約和退市的預計時間表;MorphoSys的計劃、目標、期望和意圖;以及MorphoSys和諾華製藥的財務狀況、業績和業務。 關於MorphoSys 前瞻性聲明 從業務活動、財務狀況、措施、定製內容和存儲內部控制等方面發現的與可比企業、可比的市場股權或生產過程相關的差異。也可能會發生環境、政治、法規、經濟和其他重大風險或不確定因素的變化等。在風險確認後,德國生物製藥公司M0rphosys納斯達克代碼MOR將被註銷。 更多信息,請聯繫:
2024年12月7日 CET/CESt發佈企業新聞,由EQS News - EQS Group AG的服務傳送。 |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | |
ISIN: | DE0006632003 |
WKN: | 663200 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1945523 |
語言: | 英語 |
公司: | morphosys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
德國 | |
電話: | 電話:+49 (0)89 899 27-0 |
傳真: | 傳真:+49 (0)89 899 27-222 |
電子郵件: | investors@morphosys.com |
閱讀我們的年報 | |
ISIN代碼 : | DE0006632003 |
WKN: | 663200 |
上市: | 法蘭克福(主板)上市、柏林、杜塞爾多夫、漢堡、漢諾威、慕尼黑、斯圖加特、Tradegate Exchange非官方上市、納斯達克 |
EQS新聞 ID: | 1945523 |
End of News | EQS News Service |
新聞結束 | EQS新聞服務 |
譯文內容由第三人軟體翻譯。